NCT01176851已完成1 期
Pharmacokinetic, Randomized, Open-label, Single-dose, 3-way Cross-over Study of Intravenous and Inhaled Glycopyrrolate With or Without Charcoal Block Ingestion in Healthy Volunteers.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Plasma and urine pharmacokinetics of glycopyrrolate
研究概览
简要总结
The purpose of this study is to investigate the pharmacokinetics, the absolute bioavailability and the lung bioavailability of inhaled Glyco pMDI.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and females healthy volunteers aged 18-65 years;
- •Written informed consent obtained before the first trial related activity.
- •Able to understand the study procedures, the risks involved and ability to be trained to use the devices correctly.
- •Body Mass Index (BMI) between 18.0 and 32.0 kg/m2;
- •Non- or ex-smokers who smoked < 5 pack years;
- •Good physical and mental status;
- •Normal blood pressure and heart rate;
- •Electrocardiogram (ECG)considered as normal;
- •Results of laboratory tests within the normal ranges.
- •Lung function measurements within the normal ranges.
排除标准
- •Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before inhalation of the study medication;
- •Pregnant or lactating women or women of childbearing potential, UNLESS they are using one or more of the acceptable methods of contraception. Male subjects not willing to use an acceptable method of contraception.
- •Positive HIV1 or HIV2 serology;
- •Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C;
- •Unsuitable veins for repeated venipuncture;
- •History of substance abuse or drug abuse within 12 months prior to screening visit or with a positive urine drug screen at screening;
- •Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation;
- •Clinically significant and uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol;
- •Participation in another clinical trial less than 8 weeks prior to inhalation of the study medication; participation in another clinical trial using radioactive material within 1 calendar year;
- •History of hypersensitivity to M3 Antagonists or any of the excipients contained in any of the formulations used in the trial;
- •Any drug treatment, including prescribed or OTC medicines as well as vitamins, homeopathic remedies etc, taken in the 14 days (2 months for enzyme-inducing or enzyme-inhibiting drugs e.g., glucocorticoids, phenobarbital, isoniazid) preceding the first intake of the study drug, with the exception of occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days for mild non-excluding conditions).
- •Treatment within the previous 3 months with any drug known to have a well defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole).
- •Subjects who refuse to abstain from alcohol or caffeine containing foods or beverages or grapefruit containing foods or beverages from 48 hour prior to the first intake of study medication and for the entire duration of the study.
- •Heavy caffeine drinker.
研究组 & 干预措施
Glyco pMDI
Experimental
Glyco pMDI 100 µg
干预措施: Glycopyrrolate (Drug)
Glyco pMDI Charcoal
Experimental
Glyco pMDI 100 µg + charcoal block
干预措施: Glycopyrrolate (Drug)
Glyco IV injection
Active Comparator
Glyco solution for injection 100 µg
干预措施: Glycopyrrolate (Drug)
结局指标
主要结局
Plasma and urine pharmacokinetics of glycopyrrolate
时间窗: over 24 h post dose
次要结局
- Lung function parameters(over 24 h post dose)
- Cardiovascular parameters(over 24 h post dose)
- Clinical chemistry and haematology, urinalysis(over 24 h post dose)
- Adverse Events(during the whole study period)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male SubjectsHealthy ParticipantsNCT06678542Jiangxi Qingfeng Pharmaceutical Co. Ltd.36
已完成
1 期
A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male PatientsHealthy Male ParticipantsNCT01707342Janssen R&D Ireland6
已完成
1 期
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015KBioavailability of ASP015KPharmacokinetics of ASP015KHealthy SubjectsNCT01486017Astellas Pharma Inc30
已完成
不适用
Bioavailability and Pharmacodynamic study of Disgren EC capsule(Triflusal 300mg)Diseases of the circulatory systemKCT0001299Kyungpook National University Hospital38
已完成
1 期
Pharmacokinetics of 3 Formulations of Ibuprofen SuppositoriesHealthyNCT00921830Johnson & Johnson Consumer and Personal Products Worldwide25